G1 Therapeutics Stock Target Price and Analyst Consensus
GTHX Stock | USD 4.10 0.01 0.24% |
The current analyst and expert consensus on G1 Therapeutics is Buy, with 2 strong buy opinions. The current projected G1 Therapeutics target price consensus is 9.50 with 6 analyst opinions. The most common way G1 Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview G1 Therapeutics executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on G1 Therapeutics. We strongly encourage you to use your own analysis of G1 Therapeutics to validate this buy or sell advice. G1 Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected G1 Therapeutics target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on G1 Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.
Lowest Forecast 8.65 | Highest Forecast 10.55 | Target Price 9.5 |
GTHX |
It's important to approach G1 Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize G1 Therapeutics price targets
G1 Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using G1 Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at G1 Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if G1 Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional G1 Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of G1 Therapeutics is a key component of G1 Therapeutics valuation and have some predictive power on the future returns of a G1 Therapeutics.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of G1 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.Adviser Favorites Invested a lot of shares | ||
Manufacturing Invested over 40 shares | ||
Hedge Favorites Invested over 50 shares | ||
ESG Investing Invested few shares | ||
Dividend Beast Invested over 70 shares | ||
Momentum Invested over 200 shares | ||
Automobiles and Trucks Invested over 200 shares | ||
Check out Macroaxis Advice on G1 Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
The data published in G1 Therapeutics' official financial statements usually reflect G1 Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of G1 Therapeutics. For example, before you start analyzing numbers published by GTHX accountants, it's critical to develop an understanding of what G1 Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of G1 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, G1 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in G1 Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of G1 Therapeutics. Please utilize our Beneish M Score to check the likelihood of G1 Therapeutics' management manipulating its earnings.